Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer
Speaker: N. Shore, Myrtle Beach (US) Event: 35th Annual EAU Congress – Virtual (EAU20V)
Leave a Reply
Want to join the discussion?Feel free to contribute!